P
Philip Lackey
Researcher at Carolinas Healthcare System
Publications - 12
Citations - 557
Philip Lackey is an academic researcher from Carolinas Healthcare System. The author has contributed to research in topics: Viral load & Regimen. The author has an hindex of 3, co-authored 10 publications receiving 547 citations.
Papers
More filters
Journal ArticleDOI
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Joseph J. Eron,Patrick Yeni,Joseph C. Gathe,Vicente Estrada,Edwin DeJesus,Schlomo Staszewski,Philip Lackey,Christine Katlama,Benjamin Young,Linda Yau,Denise H. Sutherland-Phillips,Paul Wannamaker,Cindy Vavro,Lisa G. Patel,Jane Yeo,Mark S. Shaefer +15 more
TL;DR: Fosamprenavir-ritonavir twice daily in treatment-naive patients provides similar antiviral efficacy, safety, tolerability, and emergence of resistance as lopinavir-ritis-rit onavir, each in combination with abacvir-lamivudine.
Journal ArticleDOI
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Kimberly Y. Smith,Parul Patel,Derek M. Fine,Nicholaos C. Bellos,Louis Sloan,Philip Lackey,Princy Kumar,Denise H Sutherland-Phillips,Cindy Vavro,Linda Yau,Paul Wannamaker,Mark S. Shaefer +11 more
TL;DR: Both ABC/3TC and TDF/FTC provided comparable antiviral efficacy, safety, and tolerability when each was combined with lopinavir/ritonavir in treatment-naive patients.
Journal ArticleDOI
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.
Anthony Mills,Laurence Brunet,Jennifer S Fusco,Michael Wohlfeiler,Cindy Garris,Alan Oglesby,Joseph M. Mrus,Philip Lackey,Gregory Fusco +8 more
TL;DR: In this large cohort representative of PLWH in care in the US, ART-naïve PLWH prescribed DTG had betterVirologic outcomes than RAL and DRV, but had virologic failure risks comparable to EVG, although RALand DRV were preferentially prescribed to sicker individuals.
Journal ArticleDOI
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Philip Lackey,Anthony Mills,Felix Carpio,Ricky Hsu,Edwin DeJesus,Gerald Pierone,Cassidy Henegar,Jennifer S Fusco,Gregory Fusco,Mike Wohlfeiler +9 more
TL;DR: Patients receiving treatment-experienced HIV-infected patients initiating their first regimen containing ABC/3TC in combination with any PI appear to experience similar treatment benefit to patients taking ABC/ 3TC with other PIs in terms of achieving suppression, as well as absolute reductions in viral load and CD4 lymphocyte gains.
Journal ArticleDOI
936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
TL;DR: Investigation body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR were rare in this large cohort of patients initiating DTG, EVG, RAL, or DRV-based regimens.